SIDEBAR: Stay Tuned for More Information on Neuropathy-related Genes

Get Permission

Daniel F. Hayes, MDAccording to Daniel F. Hayes, MD, of the University of Michigan, Ann Arbor, who moderated the Best of ASCO® Miami conference, taxane-induced neuropathy is a more complicated story than the study by Schneider and colleagues may suggest.

“There are now three observations regarding inherited germline single-nucleotide polymorphisms (SNPs) and the risk of taxane-induced neuropathy, each using samples from North American breast cancer group trials and each completely different,” he told The ASCO Post. In addition to Schneider’s trial based on E5103, tissue samples from SWOG S0221 and CALGB 40101 also Hayes quotedemonstrate significant—though disparate—genetic associations. The investigators from these three studies are now collaborating in an effort to validate one or more of these variants. “Each investigator has made observations in one dataset, and they will now take that data and apply it to the other datasets,” Dr. Hayes said.

“Right now, I would not use any of the data to withhold taxanes, but I foresee a day when we will be able to predict who will get toxicity,” he said. “We will then be able to determine who should perhaps not receive a taxane in spite of its benefit, or should get one taxane vs the other.” ■

Related Articles

Breast Cancer Studies Explore Wide Variety of Prevention and Treatment Strategies

At the Best of ASCO® meeting in Miami, Harold Burstein, MD, PhD, Dana-Farber Cancer Institute, Boston, and Carey K. Anders, MD, University of North Carolina at Chapel Hill, presented high-impact breast cancer abstracts that will enable clinicians to optimize their use of radiotherapy and biologics. ...

SIDEBAR: Studies Sparked Questions to Breast Cancer Specialists

Based on the MAP.3 findings, should we be using exemestane to prevent breast cancer in high-risk patients?

Harold Burstein, MD, PhDDr. Harold Burstein: The risk of developing breast cancer was 2.5% in the placebo arm, vs 1% to 1.5% risk with exemestane. Also, the cancers that were avoided were probably ones with good...

SIDEBAR: Other Breast Cancer Studies of Note

Harold Burstein, MD, PhDAt this year’s Best of ASCO® Miami meeting, Harold Burstein, MD, PhD, discussed several studies he found interesting and relevant to clinical practice.

Genomic Assays

One study examined two genomic assays for ER-positive breast cancer, Oncotype DX and PAM50, and found considerable overlap among...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.